The FDA Looks at D8
By the time the authorities get around to questioning it, you’ll have collected more than enough revenue to pay your legal fees.
Select Page
Sometimes it’s new information. Sometimes it’s helpful, hopeful news. And sometimes it’s clickbait, bad information or useless.
by C. Scott McMillin | May 26, 2022 | In the News | 0 |
By the time the authorities get around to questioning it, you’ll have collected more than enough revenue to pay your legal fees.
by C. Scott McMillin | May 23, 2022 | Public Health | 0 |
by C. Scott McMillin | May 5, 2022 | Public Policy | 0 |
by C. Scott McMillin | Apr 25, 2022 | Public Policy | 0 |
by C. Scott McMillin | Mar 21, 2022 | In the News | 0 |
by C. Scott McMillin | Mar 14, 2022 | In the News | 0 |
by C. Scott McMillin | Feb 17, 2022 | Public Policy | 0 |
The smaller, local, independent, licensed growers – intended to benefit from legalization– have instead found themselves all but shut out of the market, unable to compete with much cheaper offerings.
Read Moreby C. Scott McMillin | Feb 7, 2022 | In the News | 0 |
A functioning pill mill can be extraordinarily lucrative for those who own or operate them. The profits go untaxed, remember.
Read Moreby C. Scott McMillin | Jan 31, 2022 | Addiction, Public Policy | 0 |
I can see how Smartphones could just make a bad situation worse. Legislation, on the other hand, has a long way to go simply to catch up.
Read Moreby C. Scott McMillin | Jan 17, 2022 | In the News | 0 |
In COVID terms, it’s as contagious as omicron, as fatal as delta. And targeted at the young, making use of their favorite platforms.
Read Moreby C. Scott McMillin | Jan 10, 2022 | In the News | 0 |
Juries are less interested in subtle legal distinctions than a judge can be.
Read Moreby C. Scott McMillin | Jan 6, 2022 | Addiction, Families, In the News | 0 |
Research into long-term recovery has been prominent in the past — why not revive it?
Read Moreby C. Scott McMillin | Dec 30, 2021 | Addictive Substances, In the News | 0 |
From the alcoholic beverage industry’s viewpoint, the pandemic has a pronounced silver lining. Sales are up and allegedly likely to continue at higher levels even as the pandemic finally fades.
Read Moreby C. Scott McMillin | Dec 27, 2021 | Public Policy | 0 |
…it’s foolish to expect an industry built around making, distributing, and selling (for immense profit) abusable substances to regulate themselves.
Read Moreby C. Scott McMillin | Dec 20, 2021 | In the News | 0 |
Mike insists that everybody who knows him has commented on how much better he seems since he started up with the toad venom. Of course, I’m not sure how often people are willing to openly contradict Iron Mike.
Read Moreby C. Scott McMillin | Dec 2, 2021 | Public Policy | 0 |
…the narrower the gap between the incident and its consequences, the greater the deterrent value in terms of the offender’s future behavior.
Read Moreby C. Scott McMillin | Nov 29, 2021 | In the News | 0 |
If so many players were involved, how can drug makers bear primary responsibility? Even if to the layperson’s mind, they richly deserve it.
Read Moreby C. Scott McMillin | Nov 18, 2021 | Public Health | 0 |
Some will represent the very best medicine has to offer, and others will be, well, not so great.
Read More